Linked Life Data

21324687

Source:http://linkedlifedata.com/resource/pubmed/id/21324687

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21324687rdf:typepubmed:Citationlld:pubmed
pubmed-article:21324687lifeskim:mentionsumls-concept:C0006118lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0005854lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0031164lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C1710493lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:21324687lifeskim:mentionsumls-concept:C2350866lld:lifeskim
pubmed-article:21324687pubmed:issue6lld:pubmed
pubmed-article:21324687pubmed:dateCreated2011-3-7lld:pubmed
pubmed-article:21324687pubmed:abstractTextNovel second generation analogs of eribulin mesylate, a tubulin agent recently approved for the treatment of breast cancer, are reported. Our recent efforts have focused on expanding the target indications for this class of compounds to other tumor types. Herein, we describe the design, synthesis and evaluation of eribulin analogs active against brain tumor cell lines in vitro and corresponding brain tumor models in mice. Attenuation of basicity of the amino group(s) in the C32 side-chain region led to compounds with lower susceptibility to P-gp mediated drug efflux, allowing these compounds to permeate through the blood-brain barrier. In preclinical in vivo studies, these compounds showed significantly higher levels in the brain and cerebrospinal fluid as compared to eribulin. In addition, analogs within this series showed antitumor activity in an orthotopic murine model of human glioblastoma.lld:pubmed
pubmed-article:21324687pubmed:languageenglld:pubmed
pubmed-article:21324687pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21324687pubmed:citationSubsetIMlld:pubmed
pubmed-article:21324687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21324687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21324687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21324687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21324687pubmed:statusMEDLINElld:pubmed
pubmed-article:21324687pubmed:monthMarlld:pubmed
pubmed-article:21324687pubmed:issn1464-3405lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:HuYongboYlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:ZhangHuimingHlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:KumarVipulVlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:DuHongHlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:ChengHongshen...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:JiangYiminYlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:TowleMurray...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:LittlefieldBr...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:YuMelvin JMJlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:NarayanSridha...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:SeletskyBoris...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:ZhengWanjunWlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:SaxtonPhilipPlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:TendykeKarenKlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:LewisBryan...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:CarlsonEric...lld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:CondonKristaKlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:EckleySeanSlld:pubmed
pubmed-article:21324687pubmed:authorpubmed-author:SchuckEdgarElld:pubmed
pubmed-article:21324687pubmed:copyrightInfoCopyright © 2011 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:21324687pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21324687pubmed:day15lld:pubmed
pubmed-article:21324687pubmed:volume21lld:pubmed
pubmed-article:21324687pubmed:ownerNLMlld:pubmed
pubmed-article:21324687pubmed:authorsCompleteYlld:pubmed
pubmed-article:21324687pubmed:pagination1639-43lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:meshHeadingpubmed-meshheading:21324687...lld:pubmed
pubmed-article:21324687pubmed:year2011lld:pubmed
pubmed-article:21324687pubmed:articleTitleNovel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.lld:pubmed
pubmed-article:21324687pubmed:affiliationEisai Product Creation Systems, Eisai Inc., Andover, MA 01810, USA. Sridhar_Narayan@eisai.comlld:pubmed
pubmed-article:21324687pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:21324687lld:chembl